raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
Other Name: MK0518
Other Name: ISENTRESS™
- HIV positive patients who have limited or no treatment options and have documented resistance
- Patient has previously been on MK0518 therapy
Merck Sharp & Dohme Corp.
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.